Professor and Head of the Division of Molecular Therapeutics in MCB, UC Berkeley
Founder, Nurix and Lyterian Therapeutics
Excited about stress responses, ubiquitin, proteasome, targeted protein degradation, drug discovery
Howard Hughes Medical Institute (HHMI) believes in the power of individuals to advance science through research and science education, making discoveries that benefit humanity.
